Pneumococcal Protein Vaccine Safety and Immunogenicity Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observer-blind, randomised, vaccine-controlled, vaccine trial to determine the safety and immunogenicity of a pneumococcal protein vaccine. It will use an age step-down approach beginning with adults, then toddlers then infants, with data safety review at each stage before stepping down to the next age group. Adults and toddlers will receive the same dose of this three-protein (trivalent) vaccine (PcpA, PhtD, and PlyD1 proteins) at 50µg each. Infants will then be started at a low dose (10 µg), then medium dose (25µg) then high dose (50µg), with safety reviews at each stage before ascending to the next highest dose. Infants will also receive concomitant standard EPI childhood vaccines. Safety will be assessed by close monitoring beginning on the day of vaccination (day 0) and for the subsequent seven days, with recording of solicited and non-solicited adverse events. Immunogenicity will be assessed by specific antibody response to the three proteins. The study aims to recruit 280 study subjects across all age groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants

NCT01446926

Pneumonia Pneumococcal Infections Streptococcus Pneumoniae Infections

COMPLETED PHASE1

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

NCT00761631

Healthy Subjects

COMPLETED PHASE3

Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso

NCT01577771

Pneumococcal Infections

COMPLETED PHASE4

Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults

NCT01444352

Pneumococcal Infections Streptococcus Pneumoniae Infections Pneumococcal Pneumonia

COMPLETED PHASE1

Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine

NCT04087460

Pneumonia Respiratory Tract Diseases Respiratory Tract Infections

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase I, single-center, randomized, placebo-controlled, step-down observer-blind study to assess the safety and immunogenicity of a single injection PPrV vaccine containing 50 µg of each protein (PcpA, PhtD and PlyD1) withadjuvant in healthy adults and toddlers, and of 3 injections in healthy infants (following the Expanded Program on Immunization \[EPI\] schedule) at 3 ascending dose levels (all adjuvanted 10, 25, and 50µg of each protein per dose level; with an additional un-adjuvanted formulation at 25 µg of each protein per dose level).

Overall, there will be 5 Cohorts. In Cohort I, adults will receive 1 injection of adjuvanted 50 µg PcpA, PhtD and PlyD1 PPrV vaccine (high dose) or placebo.

In Cohort II, toddlers will receive 1 injection of adjuvanted 50 µg PcpA, PhtD and PlyD1 PPrV vaccine or placebo.

In Cohorts III, IV and V, infants will receive 3 injections of one of the following PPrV vaccine formulations: adjuvanted 10 µg each PcpA, PhtD and PlyD1 (low dose), adjuvanted 25 µg each PcpA, PhtD and PlyD1 (middle dose), unadjuvanted 25 µg each PcpA, PhtD and PlyD1 (middle dose un-adjuvanted), or adjuvanted 50 µg each PcpA, PhtD and PlyD1 (high dose) or placebo, according to the EPI schedule (at 6 weeks, 10 weeks and 14 weeks), as well as concomitant applicable standard of care childhood vaccines ( Quinvaxem® \[DTwP-HepB-Hib\] vaccine, Bacillus Calmette-Guérin vaccine (BCG) (if not received at birth), and oral poliomyelitis vaccine \[OPV\]).

As a safety precaution, this trial will use a step-down approach for enrollment: for adults, 1 vaccination and acceptable review of safety data collected through Day 7 after injection, followed by enrollment of toddlers, 1 vaccination and acceptable review of safety data collected through Day 7 after injection, and then enrollment of infants (3 injections, EPI schedule). For infants, step-wise dose ascension is conditional upon acceptable safety reviews, which will be conducted after completion of the third vaccination of the EPI series at each dose level, using safety data collected through Day 7 after each of the vaccinations.

An Independent Data Monitoring Committee (IDMC) will be established for safety oversight of this study, for which a formal IDMC charter will be developed. For all safety reviews, blinded safety data will be provided to the Sponsor's Safety Management Team (SMT). The review will be performed by the SMT with presentation of findings, as per standard early safety review process, to the Sponsor's Safety Management Oversight Team (SMOT) in order to assess whether proceeding to the next ascending dose level is appropriate. The results will be communicated to the IDMC after each review. A formal IDMC review is proposed following completion of the Cohort II (toddler) safety review, prior to enrollment of Cohorts III, IV, and V (infants).

The study scheme is summarized in Figure 1, and details of safety reviews are described in the periodic safety data review (SDR) section. Electronic data capture (EDC) will be used for the collection of data generated in this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adverse Effects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pneumococcal protein vaccine

Group Type ACTIVE_COMPARATOR

Pneumococcal protein vaccine

Intervention Type DRUG

One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Pneumococcal protein vaccine

Intervention Type DRUG

Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Pneumococcal protein vaccine

Intervention Type DRUG

Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Pneumococcal protein vaccine

Intervention Type DRUG

Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM

Pneumococcal protein vaccine

Intervention Type DRUG

Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Placebo

Group Type PLACEBO_COMPARATOR

Pneumococcal protein vaccine

Intervention Type DRUG

One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Pneumococcal protein vaccine

Intervention Type DRUG

Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Pneumococcal protein vaccine

Intervention Type DRUG

Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Pneumococcal protein vaccine

Intervention Type DRUG

Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM

Pneumococcal protein vaccine

Intervention Type DRUG

Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pneumococcal protein vaccine

One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Intervention Type DRUG

Pneumococcal protein vaccine

Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Intervention Type DRUG

Pneumococcal protein vaccine

Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Intervention Type DRUG

Pneumococcal protein vaccine

Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM

Intervention Type DRUG

Pneumococcal protein vaccine

Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

pneumococcal common protein vaccine pneumococcal common protein vaccine pneumococcal common protein vaccine pneumococcal common protein vaccine pneumococcal common protein vaccine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteers

Exclusion Criteria

* Acute or chronic condition that would interfere with the ability to complete the observation period
* Allergy to egg or other vaccine components
* Receipt of antibiotics
* Receipt of immune modulating or blood products
* Receipt of pneumococcal vaccine or concomitant participation in other vaccine or drug trials

Minimum Eligible Age

6 Weeks

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes